Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly...
Transcript of Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly...
![Page 1: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/1.jpg)
Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers:An Update from ASCO 2018
Lori J. Wirth, Maria E. Cabanillas, Eric J. Sherman, Ben Solomon, Sophie LeBoulleux, Bruce Robinson, Matthew H. Taylor, Todd Bauer, Jyoti D. Patel, Karen Reckamp, Jochen H. Lorch, Daniel S. W. Tan, Valentina Boni, Steve Smith, Brian Tuch, Kevin Ebata, Edward Y. Zhu, Michele Nguyen, Xin Huang, Scott Cruickshank, S. Michael Rothenberg, Geoffrey R. Oxnard, Benjamin Besse, Martin Schlumberger, Alexander Drilon, Vivek Subbiah, Manisha H. Shah
Massachusetts General Hospital Cancer Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Peter MacCallum Cancer Centre, InstitutGustave Roussy, Royal North Shore Hospital, Oregon Health and Science University, Sarah Cannon Research Institute/Tennessee Oncology, University of Chicago, City of Hope National Medical Center, Dana-Farber Cancer Institute, National Cancer Centre Singapore, START Madrid CIOCC Hospital Universitatio Sanchinarro, Loxo Oncology, The Ohio State University Comprehensive Cancer Center
88th Annual Meeting of the American Thyroid Association, Oct 3-7, 2018
![Page 2: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/2.jpg)
Disclosures
![Page 3: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/3.jpg)
RET is activated by two major mechanisms in cancer
![Page 4: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/4.jpg)
LOXO-292 is a potent and selective RET inhibitor
![Page 5: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/5.jpg)
LIBRETTO-001: phase I dose escalation and pharmacokinetics
![Page 6: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/6.jpg)
RET-altered thyroid cancers: patient demographics and molecular features
![Page 7: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/7.jpg)
LOXO-292 safety profile
![Page 8: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/8.jpg)
Efficacy of LOXO-292 in RET-mutant MTC and RET fusion-positive thyroid cancer (RECIST 1.1)
40
![Page 9: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/9.jpg)
Duration of LOXO-292 treatment in RET-mutant MTC and RET fusion-positive thyroid cancer
![Page 10: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/10.jpg)
Substantial decline in MTC tumor markers
![Page 11: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/11.jpg)
Hereditary RET V804M-mutant MTC response to LOXO-292
![Page 12: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/12.jpg)
CCDC6-RET fusion-positive anaplastic thyroid cancer response to LOXO-292
![Page 13: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/13.jpg)
Conclusions
![Page 14: Clinical Activity of LOXO-292, a Highly Selective RET ...Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET-Altered Thyroid Cancers: An Update from](https://reader034.fdocuments.net/reader034/viewer/2022042308/5ed4b9a70b1c4b116053ba42/html5/thumbnails/14.jpg)
Acknowledgements
With thanks to
• LOXO-292 patients, families, and caregivers
• LOXO-292 investigators and research staff
• International Thyroid Oncology Group (ITOG)
• Alturas Analytics
• Array BioPharma